A record of what JM Financial Analysis said publicly, with the source. Not advice.
“JM Financial holds the highest price target for Neuland Laboratories at ₹25,819, implying a significant upside potential from current levels. This bullish stance is likely driven by the company's strong Q1 results, which exceeded analyst expectations with substantial year-on-year growth in revenue, EBITDA, and net profit, despite sequential declines attributed to the lumpy nature of the CDMO business.”
JM Financial Analysis’s track record (trackable calls only): 213 graded calls · 95% CI 41–54%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹25,819, as stated.
Window: 12 months, the default when no time frame is stated.
Window still open: no verdict until a close reaches a level or the window ends.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.